 - Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVVE U.S. pivotal trial for VenoValve - VenoValve is a potential treatment for approximately 2.4 million U.S. patients that suffer from severe Chronic Venous Insufficiency in the deep veins of their legs IRVINE, CA ACCESSWIRE August 3, 2021 Hancock Jaffe Laboratories, Inc. NASDAQ:HJLI Hancock Jaffe or the Company, a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration FDA has granted Breakthrough Device Designation status to the VenoValve, the Companys lead product, which is currently set to begin its U.S. pivotal trial. The FDAs Breakthrough Devices Program was established to enable priority review for devices that provide more effective treatment or diagnosis of life threatening or irreversibly debilitating diseases or conditions. 